These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20028401)

  • 21. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
    Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY
    Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
    Shah NP; Skaggs BJ; Branford S; Hughes TP; Nicoll JM; Paquette RL; Sawyers CL
    J Clin Invest; 2007 Sep; 117(9):2562-9. PubMed ID: 17710227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
    Hanfstein B; Müller MC; Kreil S; Ernst T; Schenk T; Lorentz C; Schwindel U; Leitner A; Hehlmann R; Hochhaus A
    Haematologica; 2011 Mar; 96(3):360-6. PubMed ID: 21134983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
    Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
    Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
    Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
    Hochhaus A; La Rosée P; Müller MC; Ernst T; Cross NC
    Cell Cycle; 2011 Jan; 10(2):250-60. PubMed ID: 21220945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
    von Bubnoff N; Veach DR; van der Kuip H; Aulitzky WE; Sänger J; Seipel P; Bornmann WG; Peschel C; Clarkson B; Duyster J
    Blood; 2005 Feb; 105(4):1652-9. PubMed ID: 15459011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
    Wu J; Meng F; Ying Y; Peng Z; Daniels L; Bornmann WG; Quintás-Cardama A; Roulston D; Talpaz M; Peterson LF; Donato NJ
    Leukemia; 2010 Apr; 24(4):869-72. PubMed ID: 20111070
    [No Abstract]   [Full Text] [Related]  

  • 34. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
    Weisberg E; Choi HG; Ray A; Barrett R; Zhang J; Sim T; Zhou W; Seeliger M; Cameron M; Azam M; Fletcher JA; Debiec-Rychter M; Mayeda M; Moreno D; Kung AL; Janne PA; Khosravi-Far R; Melo JV; Manley PW; Adamia S; Wu C; Gray N; Griffin JD
    Blood; 2010 May; 115(21):4206-16. PubMed ID: 20299508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
    Liu J; Zhang Y; Huang H; Lei X; Tang G; Cao X; Peng J
    Chem Biol Drug Des; 2021 Mar; 97(3):649-664. PubMed ID: 33034143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
    Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.
    Tauchi T; Okabe S; Ashihara E; Kimura S; Maekawa T; Ohyashiki K
    Oncogene; 2011 Jun; 30(24):2789-97. PubMed ID: 21278787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.